How the CCDC92 gene affects heart and blood vessel disease
CCDC92 and cardiovascular disease
This research looks at whether a gene called CCDC92 in blood vessel muscle cells promotes artery plaque and raises heart disease risk in people with type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11393126 on NIH RePORTER |
What this research studies
If you have type 2 diabetes, this research uses mouse models with the CCDC92 gene turned off and lab studies of blood vessel muscle cells to understand how CCDC92 affects artery plaque and insulin resistance. Researchers will study cell-level processes, especially the lysosomal pathway, and examine tissues under the microscope to see how changes in CCDC92 alter smooth muscle cell behavior. The team builds on human genetic links between CCDC92 and diabetes/coronary heart disease and on mouse results showing less atherosclerosis after Ccdc92 deletion. Most work is done in the lab at Ohio State University, with the goal of pointing to future treatments that could lower heart attack and stroke risk in people with diabetes.
Who could benefit from this research
Good fit: People with type 2 diabetes who are concerned about atherosclerosis, coronary artery disease, or elevated cardiovascular risk would be the most relevant group for future trials based on this work.
Not a fit: People without diabetes or whose heart conditions are not caused by atherosclerosis are less likely to benefit directly from this research.
Why it matters
Potential benefit: Could identify a new target for therapies that reduce atherosclerosis and cardiovascular events in people with type 2 diabetes.
How similar studies have performed: Human genetic studies have linked CCDC92 variants to diabetes and heart disease and mouse experiments showed benefit when Ccdc92 was deleted, but testing therapies targeting CCDC92 in people is still novel.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Fan, Yanbo — Ohio State University
- Study coordinator: Fan, Yanbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.